Published in Blood Weekly, January 19th, 2006
In addition, FG-2216 prevented reduction in hemoglobin levels due to phlebotomy in this model of chronic anemia. There were no clinical adverse events or significant changes in serum chemistry or renal or hepatic parameters observed over the treatment period.
The study was conducted by the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.